Compare MUX & OBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MUX | OBX |
|---|---|---|
| Founded | 1979 | 2015 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 733.1M | 848.8M |
| IPO Year | 1994 | 2026 |
| Metric | MUX | OBX |
|---|---|---|
| Price | $9.17 | $11.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $28.40 | ★ $38.67 |
| AVG Volume (30 Days) | ★ 1.3M | 541.6K |
| Earning Date | 11-09-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $197,553,000.00 | N/A |
| Revenue This Year | $19.23 | N/A |
| Revenue Next Year | $34.88 | N/A |
| P/E Ratio | $96.10 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.59 | $9.60 |
| 52 Week High | $29.70 | $39.00 |
| Indicator | MUX | OBX |
|---|---|---|
| Relative Strength Index (RSI) | 22.06 | 42.10 |
| Support Level | N/A | $11.84 |
| Resistance Level | $20.62 | $15.87 |
| Average True Range (ATR) | 0.82 | 1.60 |
| MACD | -0.40 | -0.03 |
| Stochastic Oscillator | 0.34 | 43.34 |
McEwen Inc is a mining and minerals production and exploration company that focuses on precious and base minerals in Argentina, Mexico, and the United States. The company generates its revenue from gold and silver production. It owns and operates the wholly-owned El Gallo 1 mine in Mexico and holds a minority stake in the company that manages the San Jose mine in Argentina. Its Other operations include: Fox Complex, Gold Bar Complex, Project Fenix, and Los Azules. The company generates its revenue from gold and silver production. Its operating segments include Canada, United States, Mexico, MSC and McEwen Copper, of which it derives maximum revenue from USA.
Obsidian Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor infiltrating lymphocytes (TIL) cell therapies for the treatment of patients with solid tumors. The company's proprietary cytoDRiVE platform is versatile and allows it to leverage drug responsive domains to control protein function, with its initial focus on TIL cell therapies developed from this platform (cytoTILs). The company's flagship product candidate, OBX-115, is a novel, genetically engineered, autologous TIL cell therapy currently in a Phase 2 clinical trial for the treatment of melanoma and a Phase 1 clinical trial for the treatment of non-small cell lung cancer.